Disease-State Conditional Bioorthogonal Activation: A Hypothesis for Closed-Loop Theranostic Control of Senescent Cell–Driven Fibrotic Disease

Fibrotic lung disease lacks both a reliable measure of active disease burden and a pharmacological strategy capable of targeting senescent cells with sufficient selectivity for meaningful therapeutic benefit. This paper proposes Disease-State Conditional Bioorthogonal Activation (DCBA), a three-component theranostic platform concept in which diagnostic engagement is a chemical prerequisite for therapeutic activation. A sentinel compound undergoes intracellular priming in senescence-associated cells over an approximately 21-day design window, responding to two independent sustained biochemical signals. A subsequently administered diagnostic cofactor completes a bioorthogonal ligation, releasing a plasma reporter fragment as a proposed senescent cell burden index and generating the therapeutic activation site. A therapeutic cofactor then engages that site to initiate cell clearance. No experimental data are reported. The architecture defines a molecular control system for iterative burden reduction whose central claim — that diagnosis can be made a chemical prerequisite for therapy — is presented as a hypothesis for preclinical investigation.